Read about our latest news and business activities
CEO Linus Bosaeus and co-founder and CTO Dr. Lei Chen attended the European Society for Medical Oncology Congress 2022, to
We are delighted to share that Dr. Lei Chen has been awarded the prestigious Skapa innovation award, as winner of
With an innovative, super sensitive technology, so-called superRCA, remaining cancer cells can be detected after treatment of acute myeloid leukemia
Inte ens ett år gamla har Rarity Bioscience fått anslag från Swelife och Medtech4health. Nu hoppas Linus Bosaeus, vd på
On behalf of the sponsor, Elicera Therapeutics, Rarity is supporting the ELC301 translational study with analysis of the vector copy
Poster presentation by Lei Chen,PhD at the European Association for Cancer Research conference on Liquid Biopsy in Bergamo, Italy. The
The award from Uppsala University Innovation goes to startup companies that has successfully attracted external funding and made technological advancements.
Rarity has been awarded a grant from Swelife and Medtech4Health – Collaboration project for better health, fall 2021. The project is
The strategic recruitment extends the company’s management team and enhances their ability to execute on the mission: to deliver high
The SuperRCA technology was first developed together with hematologists to aid in ultrasensitive detection of rare mutations in leukemic variants,
Lei Chen, PhD attended the Nordic Flow Cytometry meeting in Oslo where he presented this poster on the topic of Ultra-sensitive
The Safelock technology was initially developed under the working title sRCA, or SuperRCA as in Super Rolling Circle Amplification, the
”We plan to have a fully certified product on the market by 2023, but the method is already being tested
Lei Chen, Ph.D., co-founder of Rarity Bioscience AB speaks about SafeLock assays on Uppsala University News. https://www.uu.se/nyheter/artikel/?id=17872&typ=artikel&lang=sv (Text in Swedish)
Ignite is an online matchmaking event that addresses the latest challenges of pharma and healthcare, by connecting established companies with
Co-founder of Rarity Bioscience, Lei Chen, PhD presents Rarity SafeLock, our ultra sensitive targeted mutation detection approach that outperforms ddPCR
The Board of Rarity Bioscience is pleased to announce the appointment of Linus Bosaeus as the new Chief Executive Officer
Rarity Bioscience is pleased to announce that the first seed round of has been closed. The funding comes from the
Sitemap
Contact us
